Prostate cancer treatment market on fire … Pfizer, Janssen, Bayer 3 battles

[헬스코리아뉴스 / 이충만] As the number of prostate cancer patients rapidly increases every year, the size of the prostate cancer treatment market is also expanding. Accordingly, the competition among biopharmaceutical companies to increase their market share is getting fiercer.

Prostate cancer is a malignant tumor that occurs in the prostate and is the second most common cancer in men worldwide. The incidence of prostate cancer in Korea is also increasing every year. According to the Health Insurance Review and Assessment Service, as of 2021, the total number of prostate cancer patients in Korea was 109,921, more than three times higher than in 2010 (35,688) 10 years ago. The prostate cancer treatment market has a structure that has no choice but to grow.

In fact, according to the results of a survey by Allied Market Research, a global market research company, the global prostate cancer treatment market was estimated at $6.887 billion (about 8.7 trillion won) in 2018, but by 2026, It is expected to reach $9.94 billion (about 12.5 trillion won).

Currently, the No. 1 product in the prostate cancer treatment market is Xtandi (ingredient name: enzalutamide) from Pfizer of the United States and Astellas of Japan. This treatment recorded a total of $4.39 billion (5.4 trillion won) in sales as of 2020, ranking 18th in sales among all pharmaceuticals. It is, of course, a blockbuster drug.

However, the patent for ‘Xtandi’ is expected to expire in 2027, and the full-scale release of generics is expected to continue. In order to maintain dominance in the market, Pfizer collaborated to jointly develop and sell Orgovyx (ingredient name: relugolix), a prostate cancer treatment, from Myovant Sciences, Switzerland, in December 2020. contract has been signed. [아래 관련기사 참조]

Drugs competing with Pfizer are ▲Erleada (ingredient name: apalutamide) from Johnson & Johnson of the United States and ▲Nubeqa (ingredient name: Daroluta) from Bayer, Germany. amide, darolutamide).

FDA receives Bayer ‘Newbeca’ sNDA and designates priority review

Bayer’s non-metastatic castration-resistant prostate cancer treatment ‘Nubeqa’

Among them, ‘Newbeca’ is an oral androgen receptor jointly developed by Bayer of Germany and Orion of Finland. (FDA) first approved.

Afterwards, Bayer applied for a supplemental drug approval (sNDA) for ‘Newbeca’ as a treatment for metastatic CRPC in March of this year. . From Bayer’s point of view, it is a golden opportunity to expand the indications that were limited to non-metastatic to metastatic.

This application is based on the results of a phase 3 clinical trial (trial name: ARASENS) evaluating the combination therapy of ‘Nubeca’ and ‘Taxotere’ (ingredient name: docetaxel) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). was made based on In the trial, ‘Nuveca’ combination therapy was found to reduce the risk of death by 32.5% without side effects.

Bayer has also submitted the sNDA of ‘Newbeca’ to the European Medicines Agency (EMA), Japan’s Ministry of Health, Labor and Welfare, and the Drug Evaluation Center (CDE) under the Chinese Medicines Agency (NMPA). plan.

However, competing drugs ‘Freeze’ and ‘Xtandi’ have been approved by the FDA for metastatic CRPC as well as non-metastatic CRPC in the past two years, and some analysts say that they are a bit late to catch up.

On the Frankfurt Stock Exchange, Bayer closed higher at 61.14 euros, up 1.6% from the previous day’s closing price of 60.18 euros.

‘Freeze’, successor of ‘Zytiga’, sales increased by 70% compared to the previous year

Johnson & Johnson (Jansen) head quart view [사진=2006 by Henry N. Cobb from the Pei Company, built 1983., via Wikimedia Commons]
Johnson & Johnson (Jansen) head quart view [사진=2006 by Henry N. Cobb from the Pei Company, built 1983., via Wikimedia Commons]

Johnson & Johnson (Jansen)’s ‘Freeze’ is drawing attention as a drug that closely follows ‘Xtandi’. ‘Freeze’, which was first approved by the FDA in 2018, is a follow-up drug developed as Janssen’s existing prostate cancer treatment ‘Zytiga’ (ingredient name: abiraterone acetate) expired in 2018.

‘Zytiga’ recorded sales of 3.53 billion (about 4.4 trillion won) in 2017, but due to generic competition after patent expiration, sales of 2.3 billion (about 2.9 trillion won) in 2021 has been reduced to

On the other hand, as of 2021, sales of ‘Freeze’ increased by about 70% compared to the previous year. However, it still seems to be insufficient to supplement the sales of ‘Zytiga’. The sales of ‘Freeze’ in 2020 were 760 million dollars (about 950 billion won), and in 2021, it recorded sales of 1.29 billion dollars (about 1.6 trillion won).

On the 3rd (local time) on the New York Stock Exchange, Janssen closed at $178.29, down 0.2 from the previous trading day ($178.64).

Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited


Source: 헬스코리아뉴스 – 더뉴스 by www.hkn24.com.

*The article has been translated based on the content of 헬스코리아뉴스 – 더뉴스 by www.hkn24.com. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!